analyse EU regulatory tools and incentives - in particular orphan and paediatric legislation - to use them for novel antimicrobials and innovative alternative medicinal products (e.g. vaccines, antibacterial, antifungal, antiviral agents) that currently do not generate sufficient returns on investment;
tanalizza l-istrumenti regolatorji u l-inċentivi tal-UE - b'mod partikolari l-leġiżlazzjoni pedjatrika u dwar il-mediċini orfni - biex dawn jintużaw għal prodotti mediċinali alternattivi u innovattivi antimikrobiċi ġodda (eż. tilqim, aġenti antibatteriċi, antivirali, antifungali) li bħalissa ma jiġġenerawx biżżejjed ritorn fuq l-investiment;